Clinical Trials Sponsored by Biotechnology Institute IMASD

Total 124 results

Biotechnology Institute IMASD

Unknown

Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Androgenetic Alopecia

Spain
Biotechnology Institute IMASD

Unknown

Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis

Neurotrophic Keratitis

Spain
Biotechnology Institute IMASD

Completed

Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA

Joint Disease

Spain
Fundación Eduardo Anitua
Biotechnology Institute IMASD

Completed

Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation

Sinus Floor Augmentation

Spain
Universidad de Granada
BTI Biotechnology Institute

Active, not recruiting

Plasma Rich in Growth Factors in Post-extraction Sockets

Dental Implants | Tooth Extraction

Spain
Fundación Eduardo Anitua
BTI Biotechnology Institute

Completed

Clinical Evaluation of Polytetrafluoroethylene (PTFE, MATFILL) for the Sealing of Prosthetic Chimneys.

Edentulous Alveolar Ridge

Spain
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Withdrawn

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

COVID-19
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Completed

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

COVID-19

Mexico, Argentina, Chile, Pakistan, Russian Federation
University Hospital, Ghent
Flanders Institute of Biotechnology

Completed

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) (SARPAC)

COVID-19

Belgium
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Terminated

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

COVID-19

Chile
EVIVE Biotechnology
Peking University Cancer Hospital & Institute

Unknown

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma (A-319)

Relapsed or Refractory B-cell Lymphoma
Dana-Farber Cancer Institute
Puma Biotechnology, Inc.

Terminated

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Breast Cancer

United States
University Hospital, Ghent
Flemish institute of biotechnology (VIB)

Recruiting

Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC (SingleCell)

Peritoneal Metastases

Belgium
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Intestinal Cancer

Advanced Intestinal Cancer

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Pancreatic Cancer

Unresectable Pancreatic Cancer

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Gastric Cancer

Advanced Gastric Cancer

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Liver Cancer

Liver, Cancer of, Non-Resectable

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Breast Cancer

Advanced Breast Cancer

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Lung Cancer

Small-cell Lung Cancer

China
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

Ebola Disease

Sierra Leone
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

Ebola Virus Disease

China
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Ebola Virus Disease

China
Hospital Universitario Araba
BTI Biotechnology Institute S.L; Instituto de Investigación Sanitaria BIO-ARABA

Completed

Validity of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea (APNiA)

Obstructive Sleep Apnea (OSA)

Spain
Guangzhou Institute of Respiratory Disease
GeneCast Biotechnology Co., Ltd.

Unknown

Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

NSCLC

China
St. Jude Children's Research Hospital
HudsonAlpha Institute for Biotechnology

Completed

Genetic Study of Families With High Frequency of Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Asan Medical Center
Korea Research Institute of Bioscience & Biotechnology

Completed

Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation (DNKI-II)

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia

Korea, Republic of
Asan Medical Center
Korea Research Institute of Bioscience & Biotechnology

Completed

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

Korea, Republic of
Asan Medical Center
Korea Research Institute of Bioscience & Biotechnology

Unknown

Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission (AML_AlloHCT)

Acute Myeloid Leukemia

Korea, Republic of
Asan Medical Center
Korea Research Institute of Bioscience & Biotechnology

Completed

Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (Medi-NK)

Non-small Cell Lung Cancer

Korea, Republic of
Guangzhou Institute of Respiratory Disease
GeneCast Biotechnology Co., Ltd.

Unknown

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

Lung Cancer Non-small Cell Stage IV

China
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
University of Connecticut
Biotechnology High Performance Computing Software Applications Institute

Completed

Military Alerting System for Monitoring Body Temperature During Active Cooling (MAMBA)

Hyperthermia

United States
University of Connecticut
Biotechnology High Performance Computing Software Applications Institute

Completed

Safety and Performance Monitoring During Occupational Work II (COBRAII)

Hypothermia

United States
Curevo Inc
Green Cross Corporation; IDRI; Mogam Biotechnology Research Institute

Completed

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Herpes Zoster | Varicella Zoster

United States
Dasman Diabetes Institute
Cuban Center for Genetic Engineering and Biotechnology

Completed

Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute.

Diabetic Foot
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Nerium Biotechnology

Withdrawn

Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer | Chemotherapeutic Agent Toxicity
SmartWithFood
KU Leuven; Vlaams Instituut voor Biotechnologie

Unknown

Health Improvement Through Food and Lifestyle Intervention Based On Personalized Retail Advice (FLORA)

Metabolic Syndrome | Gut Bacteria | Personalized Nutrition
Luxa Biotechnology, LLC
National Eye Institute (NEI); National Institutes of Health (NIH); Regenerative...

Recruiting

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Dry Age-related Macular Degeneration

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Puma Biotechnology, Inc.

Not yet recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Invasive Breast Lobular Carcinoma | Anatomic Stage I Breast Cancer | Anatomic Stage II Breast Cancer | Anatomic Stage III Breast Cancer

United States
Peking University Cancer Hospital & Institute
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

B-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Shanghai Kuaixu Biotechnology Co., Ltd

Recruiting

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

China
University Ghent
Merck Sharp & Dohme LLC; the Flanders Institute for Biotechnology

Completed

Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT)

Axial Spondyloarthritis

Belgium
CanSino Biologics Inc.
Beijing Institute of Biotechnology; Canadian Center for Vaccinology

Unknown

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

COVID-19

Canada
The Mediterranean Institute for the Advance of...

Not yet recruiting

The PredictPlusPrevent Study

Depression | Anxiety Disorders
Quadram Institute Bioscience
Biotechnology and Biological Sciences Research Council; European Commission

Completed

The Orange Juice and Cardiovascular Disease Study (OJ & CVD)

Cardiovascular Disease

United Kingdom
Universitaire Ziekenhuizen KU Leuven
Vlaams Instituut Biotechnologie (VIB)

Recruiting

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis (ReMiDy)

Ulcerative Colitis

Belgium
Institute of Hematology & Blood Diseases Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Not yet recruiting

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Puma Biotechnology, Inc.

Withdrawn

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma

United States
Dana-Farber Cancer Institute
Puma Biotechnology, Inc.; Translational Breast Cancer Research Consortium

Active, not recruiting

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Breast Cancer

United States
RedHill Biopharma Limited
National Cancer Institute (NCI); Duke University; Apogee Biotechnology Corporation

Terminated

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma (ABC-103)

Multiple Myeloma

United States

Clinical Trials Sponsored by Biotechnology Institute IMASD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations